Royalty Pharma (RPRX) PT Lowered to $44 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts RPRX Hot Sheet
Price: $67.18 +1.90%
Rating Summary:
12 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
12 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
Morgan Stanley analyst Terence Flynn lowered the price target on Royalty Pharma (NASDAQ: RPRX) to $44.00 (from $46.00) while maintaining a Overweight rating.
You May Also Be Interested In
- JPMorgan Downgrades Banco del Bajio SA (BBAJIOO:MM) (BBAJF) to Neutral
- Catalyst Metals Ltd (CYL:AU) PT Lowered to AUD6.50 at UBS
- Capgemini SE (CAP:FP) (CAPMF) PT Raised to EUR151.80 at Deutsche Bank
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
